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Summary.-A serious limitation of chemotherapy for acute myeloid leukaemia
(AML), Hodgkins disease and some classes of breast cancer is that, even when
clinically evident disease responds well, the same chemotherapy when given during
remission does not affect the rate of relapse after chemotherapeutic or surgical
ablation of the primary disease. This cannot, in general, be caused by genetic adapta-
tion of the residual cancer cells which renders them resistant to specific drugs,
because after relapse further remissions can be obtained with the same drugs that
were ineffective by chronic administration in prolonging remission. The resistance
ofthe residual cells may arisefrom mechanisms such asinaccessibilityfor anatomical
or other reasons, or because of a change in metabolic state which causes these cells
temporarily to cease division, when they cannot be harmed by cycle-dependent drugs
and repair damage sustained from cycle-independent drugs. Limited differentiation
has been shown capable of reversal and this may be a mechanism which leads to
quiescence and associated "resistance", particularly in the case of AML. Where
such resistance occurs treatment during remission-or as an adjuvant to surgery
and radiotherapy-may have to rely on mechanisms which are independent ofcellular
proliferation such as processes associated with graft-versus-host-disease or the
induction of terminal differentiation. A model for studying the nature of resistance
of residual cancer and for testing treatments that might be active against cancer
cells in this state may be dormant metastases. The latter are malignant cells which
appear to be in peaceful co-existence with their host and which in experimental
systems have been induced to grow into lethal metastases by perturbation of the host
by surgical trauma, by hormonal manipulation or by immunosuppression.
IT IS A WIDELY ACCEPTED PREMISE in
cancer chemotherapy that the response to
treatment of clinically evident disease
provides a measure of responsiveness of
residual disease. This concept, when
coupled with the model developed by
Skipper and Schabel (cf. Schabel, 1975)
that the whole tumour burden, including
micrometastases, is reduced progressively
by chemotherapy according to first-order
kinetics, describes well the responses of
some transplanted tumours, and has pro-
vided a satisfactory explanation for the
treatment protocols which have proved
so successful in the cure of a substantial
proportion of children with acute lympho-
blastic leukaemia (ALL) who require long
periods of maintenance treatment after
complete remission has been achieved.
Such a model does not seem to apply to
all types of cancer, and there are malig-
nant diseases where clinically evident
disease responds to antiproliferative
chemotherapy, yetthesame chemotherapy
during remission does not affect the rate
of recurrence after induction by chemo-
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therapy or after complete remission by
ablation of the primary disease by surgery
or radiotherapy.
_Nature of residual disease in AJilL
The most compelling example is adult
acute myeloid leukaemia (AML) in which,
unlike ALL maintenance, chemotherapy
contributes little or nothing to the length
of remission. This was first demonstrated
(Powles et al., 1.979) as a by-product of a
controlled study on the role of immuno-
therapy, in which maintenance during
remission by inmmunotherapy only was
compared with a regimen ofchemotherapy
plus immunotherapy. Neither the length
of remission nor survival was extended bar
chemotherapy during remission (see Fig.
1). In a U.S. trial (Haskell, 1981) patients
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brought into remission by intensive treat-
ment were randomized to receive either
no maintenance treatment or repeated
rigorous courses of chemotherapy. The
rate of relapse was quite unaffected by
intensive maintenance chemotherapy.
Similar data have also come from sequen-
tial studies at St Bartholomew's Hospital
which show that maintenance chemo-
therapy did not alter the course of the
disease after remission induced by inten-
sive regimens (Lister et al., 1981). The
explanation that the residual AML cells
have become genetically resistant to the
drugs used in maintenance therapy, which
in general were those used for induction,
does not appear to apply here, since in all
3 studies it was found that patients who
had relapsed responded again to the drugs
that had been uised initially. Moreover,
the frequency of second clinical remissions
brought abouit by the same drugs was not
v-ery different from the frequency of first
remissions (Powles et al., 1979). Opera-
tionally, of course, the residual cells are
resistant, but the nature of this resistance
may lie more in their metabolic or anatom-
ical state thian in the acquisition ofspecific
resistance to the chemotherapeutic drtugs.
The status of residual tumour cells in
Hodgkin's disease and breast cancer
In Hodgkin's disease also, the length of
remission and the frequency of relapse
are not significantly influenced by pro-
longed maintenance treatment. This was
shown by Young et al. (1973) in a study
comparing mnaintenance chemotherapy
with no treatment and in an M.R.C. trial
(1 979) in which the rate of relapse was the
same in a group receiving intensive main-
tenance therapy as in a group given a less
toxic regimen. In Hodgkin's disease, as in
AML, the conventional conceptofacquired
drug resistance cannot be invoked, because
a high proportion of the relapsed patients
respond again to essentially the same
chemotherapy, which when given during
remission failed to extend it.
A case can be made that a similar situa-
tion applies to certain categories of breast
cancer. The treatmeent regimen, CMF
(cyclophosphamide, methotrexate and
5-fluorouracil) administered as an adju-
vant, treatment to patients who have been
brouight into clinical remission by surgery,
has not significantly prolonged remission
in postmenopausal women. Results of the
Milan study, quoted by Carter (1980),
show that in the control arm 51-7% were
relapse-free 4 years after surgery, com-
pared with 56-5o in the group who
received CMF. Yet, CAIF was chosen as
an adjuvant treatment because it had
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prex,iously been shown highlyr effective in
patients with advanced disease, in whom
68o% showed a marked clinical response
(Canellos et al., 1974). These findings sug-
gest that clinically evident disease can
respond better to antiproliferative chemo-
therapy than residual disease. This behav-
iour was shown strikingly in a patient
with breast cancer of Dr Trevor Powles
(Royal Marsden Hospital) who had a
massive local recurrence after surgery,
with no metastasis. The recurrent tumour
responded completely to chemotherapy,
but the patient died of a heart attack
6 months later. At postmortem examina-
tion there was no evidence of cancer at
the site of the recurrence but there were
lung secondaries. At the time of chemo-
therapy, any lung lesions must have been
much smaller than the local recurrence,
yet the lung deposits were not, eliminated,
whereas the clinically evident recurrence
was cured. It is rarely possible to get such
decisive postmortem data to illustrate
that clinically evident disease can be
eradicated by a course of chemotherapy,
but that disease which was clinically
undetectable at the time ofchemotherapy,
progressed.
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The nature of the "resistant" state
Resistance of microscopic residual can-
cer to chemotherapy when clinically evi-
dent disease responds could arise if the
residual cancer cells were mitotically
quiescent. In this state they would by
definition be refractory to cycle-depend-
ent chemotherapeutic agents. However,
thev could also show resistance to cycle-
independent agents (e.g. many of t;he
alkylating agents and ionizing radiations)
because lethal damage sustained by the
cells can be restituted if the cells are
maintained in a non-dividing but meta-
bolically active state. There are manv
instances of this in radiation biology.
Thus the fraction of mouse leukaemia cells
killed in vitro by X-rays is markedly
reduced if the cells are maintained after
irradiation for some hours at 34°C, at
which temperature they are metabolically
active but do not divide (Beer et al., 1963).
A good in vivo example of mitotically
quiescent but metabolically active cells
are the parenchymal cells of the adult
liver. If after 50 Gy to an exteriorized
liver of rats a partial hepatectomy is per-
formed, there is almost total inhibition of
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Fia. 2.-iJ 'itro glowth anl (Ilifferentiation of leukaemic cells takein from pe ipheral bloocd of patients
writh acute leukaemia. Examples of differentiation to polymorpli (a) and macrophage (b) lineages.
l)ifferentiation is measured as the progressive inciease in the number of cells with Fe receptors (i)
anct histoclhemically positive for ehloracetate esterase (A) and non-specific esterase (V). Some
populations dlifferentiate towards polymorphs an(1 this is associatedl with acquisition of cilloracetate
e(sterase, while otlhers differentiate towardIs macropliages an(l be(ome positive for non-specific
esterase (Palil et ol., 1979o; Forl)es et (o., 1981).
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mitosis if the interval between irradiation
and hepatectomy is less than a week, but
if the interval is a month the number of
mitoses following partial hepatectomy is as
high in the irradiated as in the control
liver (Weinbren et al., 1960), though with
a higher incidence of chromosome breaks
(Albert, 1958).
Different mechanisms could bring about
mitotic quiescence in cancer cells present
as disseminated micro-disease: (1) the
cells, perhaps because of their anatomical
situation, are not supplied with essential
growth factors, or (2) the cells undergo
a process akin to differentiation which is
associated with reversible cessation of
division. There are several examples (cf.
Rudland & Warburton, 1982; Yoda &
Fujimura, 1979) where, in response to
stimulisuchasdimethylsulphoxide(DMSO)
or prostaglandins, malignant cells (e.g.
mammary carcinomas, neuroblastomas,
and erythroid and myeloid leukaemias)
differentiate invitro; yet when thestimulus
to differentiation is withdrawn this process
is reversed. A reason why the cells in
clinically evident disease do not become
quiescent, when those in microscopic
disease do, could be that the tumour itself
releases a diffusible product which either
prevents differentiation or produces a
growth factor without which the tumour
cells do not proliferate. As a result, the
tumour cells within small lesions would
either differentiate or not divide, because
the local concentration of the tumour-
produced inhibitor ofdifferentiation or the
growth factor is too low. On the other
hand, in large lesions, the concentration of
the putative diffusible tumour product
would be sufficient to prevent mitotic
quiescence.
Differentiation in vitro and as xenografts of
AML cells taken from the blood of patients
The hypothesis that in some instances
the malignant cells in remission are in a
different state from clinically evident
cancer was derived in part from our studies
on differentiation of AML cells in culture
and as xenografts, and also from observa-
tions made by Clarkson et al. (1977) on the
basis of continuous in vivo labelling with
3H thymidine, which indicated that in
patients presenting with AML a few
leukaemic cells were out of cycle. There
has been a considerable amount of pub-
lished work with established AML lines
on induction in vitro of differentiation by
agents such as DMSO. We found that
without adding colony-stimulating factor
AML cells taken directly from the peri-
pheral blood of patients with a blood-cell
sorter will proliferate for a few weeks in
suspension culture, after which they stop
increasing in number, stop synthesizing
DNA and eventually the culture dies out
(Chapuis et al., 1977) (see Fig. 2). With
some populations, there are clear indica-
tions of differentiation under these culture
conditions to either neutrophils or macro-
phages, on the basis of morphology,
histochemistry and surface markers (Palu'
et al., 1979a). Using these tests, however,
there are some populations (Forbes et al.,
1981) for which no evidence of differentia-
tion can be detected in the in vitro culture,
but none the less there are indications
TABLE I.-Growvth, differentiation and regression of a population of humnan AML cells
on transplantation into immune-deprived mice*
Aveiage diameter % of cells in tumour
D)ays to excision No. of of tumour-
ofxenograft mice (cm) Fc+ NSE+t
7 :i 0*38 12 15
20 5 0 74 70 48
32 11 -
Initial cell population > 90%0 leukaemic cells, 9% Fc+, 11% NSE-.
* 2 x 106 mononuclear cells obtained on first presentation from peripheral blood of a high count patieiit
with AML were transplanted s.c. into thymectomized irradiation CBA mice (Pahi et al., 1979b).
t Nonspecific-esterase-positive.
+ All tumours totally regressedl.
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with these cells of differentiation in vivo
as xenografts.
When AML cells are transplanted s.c.
into mice which have been immuno-
suppressed by adult thymectomy and
whole-body irradiation, they grow for
2-3 weeks and then the tumours, which
are made up of < 90o of human cells
almost invariably regress (Palu et al.,
]979b). This regression is not due to an
immune rejection, since if mice in which
tumours consisting of AMIL cells have
regressed are re-inoculated with the same
population of AML cells, the latter grow
again and give rise to tumours which then
agaiin regress. The regression in vivo
appears to be associated with differentia-
tion, since the AML cells, as they grow in
the mice, progressively acquire Fc recep-
tors and esterases characteristic ofneutro-
phils or macrophages. Regression occurs
after the AML cells in the xenograft
express markers indicating differentiation
(Table I).
Initially (PalW' et al., 1979a, b) these
investigations were carried out in con-
siderable detail, using 2 populations
whichdifferentiatedrespectivelytoneutro-
phils and macrophages. We have now,
however, extended this study to 36 differ-
ent populations, but find no correlation
between prognosis and the behaviour of
TABLE II.-Growth in vitro and in vivo of Leukaemic cells from peripheral blood of 36
Patients* with AML
Growth patterin
l'oor or none
No differentiation
Granuilocytic differeIntiation
AMacrophage differentiation
Total
No. Temporary giowtlh
patients as xenografts
5 0
8 6
15 13
8 5
36
* Selected on basis of availability of leukaemic cells obtained wsrith blood-cell separator, and tberefore
biased in direction of patients witlh higlh nuimbers of cireulating leukaemie cells at presentation
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FIG. 3.-Prostaglandiris PGAI and PGA2 (0) at 10 and I/Ag/ml, but not at 0-1 jig/ml, induce
dlifferentiation towards polymorplhs (i.e. acquire chloracetate esterase, CAE) of a population of
A-ML cells in which differentiation in vitro could not otherwise be (letecte(i (Foibes et ld., 1981).
*; FCS control.
Attaine(d
remission
4 (80)
5 (62)
9 (60)
5 (62)
23 (64)
Length of
remission
> 1 year (%o)
2 (50)
1 (20)
3 (30)
2 (40)
8 (35)
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the cells in culture (Table II). The patients
whose cells did not differentiate in culture
did not fare detectably worse than those
whose cells did differentiate. However, it
must be borne in mind that the cells
when transplanted as xenografts regress
even when they do not show obvious
differentiation in culture. With a popula-
tion of AML which did not differentiate
significantly in the normal culturemedium,
Forbes et al. (1981) found that the rate of
differentiation was accelerated by adding
prostaglandin A (Fig. 3). This suggests
that differentiation of at least some AML
cell populations is capable of being
modified by physiological factors.
Dormant mnetastasis
The interpretation I have offered for
resistance of some subclinical cancer to
antiproliferative drugs is similar to one of
the mechanisms advanced for tumour
dormancy. There are many clinical instan-
ces, particularly in cancer of the breast
and melanoma, in which tumours locally
removed recur locally or as metastases
after a long disease-free interval. Tumour
dormancy can be studied in experimental
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systems. Fisher & Fisher (1959) showed
that a few tumour cells inoculated intra-
portally remained dormant within the
liver until their growth was stimulated by
unknown factors associated with hepatic
trauma. With oestrogen-dependent tum-
ours, dormancy extending for very long
periods can be detected by transplanting
the tumours into noirmal recipients, in
which no growth occurs, and then admin-
inistering oestrogen, when macroscopic
growth sets in. Noble & Hoover (1975),
Eccles & Alexander (1975) and Eccles et al.
(1980) found that dormant metastases
were commonin chemically induced rodent
sarcomas and lymphomas which did not
metastasize frequently when transplanted
to normal syngeneic animals, in which
they can be "cured" by surgical removal
of the primary implant and its draining
node. When such tumours were allowed to
grow for a set period before being excised
surgically, dormant metastases, seeded
from the primary implant before it was
excised, were revealed as lung or distant
lymph-node metastases after immuno-
suppression, especially that caused by
Cyclosporin A (Eccles et al., 1980), long
after surgery (Fig. 4). Similarly, cell sus-
PRE-IMPLANTATIONITUMOUR GROWTH PERIOD, POST EXCISION PERIOD
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FIG. 4. Effect of' one (lose of C'yclosporin A (80 mg/kg i.m.) on inci(lence of metastasis appearing
within 200 (lays from the AIC24 rat sarcoma (C refers to control group not receiving Cyclosporin A).
Cyclosporin A was administered either before inoculation of the tumour, (luring the 14 (lays of
tumour growtlh, or at different times after excision of the tumour transplant. The metastases which
arise as a result of immtunosuppression after iremoval of the primary are (lorloorlat rnoetastases
(Eccles et al., 1980). Aletastases: L=lutng; LN=Iymph no(le(s).
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pensions prepared from clinically disease-
free lungs from animals in which the
tumour had been excised gave rise to
tumours when injected into immuno-
suppressed recipients. The cells comprising
the dormant metastases are not a genetic-
ally different subpopulation with unusual
properties, because the cells in the meta-
stases induced by immunosuppression
have the same biological properties (e.g.
TD50, immunogenicity, growth rate and
metastatic potential in the normal non-
immuinosuppressed host) as those in the
primary implant.
We have not so far been able to induce
the outgrowth of dormant metastases of
carcinomas by immunosuppression, but
the existence of quiescent tumour deposits
is indicated in a number of models bv the
late appearance ofmetastases aftersurgery
The tumour cells in these late metastases,
when transplanted, grow rapidly and do
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Fic. 5. Severity of GvH (lisease ani(I recurrence of leukaernia (firom Xeid(leil et al., 1981). PIrobabilitv
of patients with actute letikaemia remaiining in remission when treate(d by total-body irradiation
an(d ani allogenceic (HLA-matcliedl) marrow transplant. Patients rlivi(led into 4 groups according to
type an(d severity of GvH reactioin.
not differ from those in the primaryx
implant; their delayed appearance indi-
cates a host-induced quiescent state.
A link between dormant metastases
and the resistance to drugs of residual
cancer is indicated bv the fact that the
dormant sarcoma and lymphoma cells are
obviouslv in an unusual state in which
they are invulnerable to immune attack.
The hosts from which the tumour had
been excised (and which harboured the
dormant metastases) rejected a second
inoculation (i.m. or s.c.) of the same
tumour cells. The cells inoculated into the
host, immunized by a growing tumour
which was excised, were killed and did not
become dormant. We have the anomaly
that dormant tumour cells persist in an
animal in which the same tumour cells
are killed when deliberately injected. A
clear demonstration ofa state ofresistance
to T-mediated immunity.
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POSSIBLE STRATEGIES FOR
TREATMENT IN REMISSION
The phenomenon that disseminated
micro-cancer can be resistant to anti-
proliferative cytotoxic agents when "bulk
disease" is responsive is demonstrated
most clearly in AML, but may apply also
to other malignant diseases. It is possible
that the refractory disseminated cells in
these clinical cancers, and the dormant
metastases in experimental animals, are
present in a mitotically quiescent state
that is reversible. For AML there are good
grounds for attributing the mitotic arrest
to differentiation.
What are the possible strategies for
destroying such quiescent cells; i.e. what
treatments could prolong remission? An
approach which may be particularly
applicable when the dormant stateisdue to
hormone dependence would be deliber-
ately to bring the cells into cycle by a
hormonal manoeuvre and to follow this
with conventional antimitotics. A second
means of dealing with such differentiated
cells would be agents promoting differ-
entiation. These can cause cancer cells to
undergo irreversible differentiation in
vitro, but we are very much in the dark
on how to proceed along such lines in vivo.
r find myself most attracted to the idea
of looking, for agents which kill cells
which are not dividing, but which yet show
a degree of selectivity based on cell type.
That such an approach is not total "pie
in the sky" comes from findings made in
experimental animals and in man that a
component of the graft-vs-host (GvH)
reaction can have an antileukaemic effect.
GvH disease) is conventionally induced by
first ablating the marrow, usually by
total-body irradiation, and then trans-
planting genetically dissimilar marrow
cells. Immunocvtes derived from the
graft attack cells of host phenotype. The
nature of the cytotoxic effector mechan-
ism of GvH disease is not known, but it
shows a remarkable tissue selectivity.
The normal tissues at high risk to the
conventional antimitotic chemotherapy
are those ofhigh turnover (i.e. marrow and
mucosae of the GI tract) but these are
unaffected in GvH disease, which pro-
duces its symptoms and can kill by
damaging the skin at the dermal-epider-
mal junction, the liver at the level of the
bile-duct epithelium and the gut by
processes which do not primarily involve
the mucosae. That GvH disease also
attacks leukaemia has been known in
experimental animals for a long time (cf.
Okunewick et al., 1981) but it has only
very recently been recognized that it may
have a role in preventing recurrence of
AMIL in man. The Seattle group (Weiden
et al., 1981) have found that recurrence of
AML can be greatly reduced if patients in
remission are given 10 Gy of total-body
irradiation followed by marrow graft.
This procedure was initiated on the
assumption that the irradiation would
eradicate residual AML cells left after
intensive chemotherapy, and the marrow
graft was given to reverse an otherwise
lethal ablation of marrow function. The
severity of the ensuing GvH disease
varies, and depends on the genetic dis-
parity between patient and marrow donor.
On analysing their results (Fig. 5) the
Seattle group found an impressive inverse
correlation between the likelihood of
leukaemic recurrence in patients with
AML who had received irradiation and
marrow grafting and the severity of the
GvH disease. The inference I draw is that
the cytotoxic effector of GvH disease kills
residual leukaemia cells which are refrac-
tory to the conventional antimitotic
agents used in cancer chemotherapy.
A major difficulty in searching for
agents which kill quiescent cancer cells is
that their activity will probably only be
revealed when tested in an adjuvant
setting. Response of bulk disease is
unlikely to provide a guide, and one may
have to abandon the precept of cancer
chemotherapists that only agents that
are effective in inducing remission are
justified in protocols designed to eradicate
residual disease.
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